Clinical trials: Herpes Zoster Infection
Post Herpetic Neuralgia (PHN)
Transcutaneous Auricular Vagus Nerve Stimulation on Post-Herpetic Neuralgia
The purpose of this study is to evaluate the therapeutic efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) in the treatment of patients with post-herpetic neuralgia (PHN).
- Trial name
- NCT07123987
- Testing
- transcutaneous auricular vagus nerve stimulation (taVNS), traditional medical treatment for PHN
- Where
- Egypt
- Volunteers
- 34 people
- Sponsor
- Mohamed Hosny Ismail Easa
Shingles
Immune Response to Shingles Vaccination
The purpose of this study is to learn more about the immune response to varicella zoster virus (VZV).
- Trial name
- NCT02624375
- Testing
- Zoster Vaccine Live
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of Washington
Herpes Zoster, Pain
The Analgesic Efficacy and Safety of Baclofen in Patients With Herpes Zoster
Herpes zoster (HZ) is characterized by a painful dermatomal rash and significantly affects quality of life, with acute pain increasing the risk of postherpetic neuralgia.
- Trial name
- NCT07378046
- Testing
- Baclofen combined conventional therapy, Conventional therapy
- Where
- China
- Volunteers
- 750 people
- Sponsor
- Beijing Tiantan Hospital
Dengue, Chikungunya
Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective
RACSMEI addresses the high burden of infectious diseases in low- and middle-income countries, including Cambodia, where limited surveillance and laboratory capacity often obscure etiologies and transmission dynamics.
- Conditions
- Dengue, Chikungunya, Zika Virus Infection, Japanese Encephalitis
- Trial name
- RACSMEI (NCT07358910)
- Where
- Cambodia
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur du Cambodge
Neuralgia, Pain
Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain
The purpose of this study is to gain initial information on the tolerability of high-dose capsaicin patches in patients with Painful Postherpetic Neuralgia.
- Conditions
- Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
- Trial name
- NCT00034710
- Testing
- Capsaicin Patch
- Where
- 8 sites in United States
- Volunteers
- 42 people
- Sponsor
- NeurogesX
Herpes Zoster
Efficacy, Immunogenicity and Safety Study of GSKs Recombinant Zoster Vaccine Shingrix (GSK1437173A) in Chinese Adults Aged ≥50 Years
The purpose of this study was to assess vaccine efficacy (VE), ability to generate immune response and safety of two doses of the recombinant subunit zoster vaccine (RZV) for prevention of Herpes Zoster (HZ) in Chinese adults…
- Trial name
- NCT04869982
- Testing
- RZV
- Where
- 6 sites in China
- Volunteers
- 6,138 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Allergy and Immunology
Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents
The purpose of this study is to measure the effect of the Shingrix vaccine on your immune system and whether that has any effect on the body's ability to fight off other infections such as COVID-19.
- Conditions
- Herpes Zoster, Allergy and Immunology, Corona Virus Infection
- Trial name
- NH-Shingrix (NCT04523246)
- Testing
- SHINGRIX (Zoster Vaccine REcombinant, Adjuvanted), Normal Saline
- Where
- United States
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Herpes Zoster
Burden of Herpes Zoster and Post-herpetic Neuralgia Among People ≥ 50 Years Old in France
The purpose of this study is to assess the burden of Herpes zoster (HZ) and post-herpetic neuralgia (PHN) among people ≥ 50 years old in France, in terms of healthcare resources used, medical direct and indirect costs, as well as…
- Trial name
- NCT02487472
- Testing
- Data collection
- Volunteers
- 106 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Herpes Zoster Vaccine
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ/su) Vaccine in Adults With Solid Tumours Receiving Chemotherapy
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults with solid tumours undergoing chemotherapy.
- Trial name
- NCT01798056
- Testing
- GSK 1437173A
- Where
- 28 sites in Canada, Czechia and 4 more
- Volunteers
- 237 people
- Sponsor
- GlaxoSmithKline
Varicella
Study on Effectiveness of 2-dose Live Attenuated Varicella Vaccine
The objective of the study is as follows: 1. To know the antibody level during different interval after received 1 dose varicella vaccine. 2.
- Trial name
- NCT02146469
- Testing
- 2 doses with an 3 months interval, A second dose with an 1 year interval, A second dose with an 3 year interval
- Where
- China
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- Shanghai Municipal Center for Disease Control and Prevention
Varicella
Safety and Efficacy of Varicella Zoster Immune Globulin (Human) VariZIG in Patients at Risk of Varicella Infection
This study is to assess VariZIG™ for the treatment of patients at risk for developing serious complications from chicken pox.
- Trial name
- NCT00338442
- Testing
- VariZIG™
- Sponsor
- Cangene Corporation
Herpes Zoster (HZ), Infectious Diseases
A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine
The goal of this clinical trial is to assess the safety and immunogenicity of an srRNA-based vaccine, JCXH-105, in the prevention of Herpes Zoster (Shingles). Subjects will be randomized to receive either JCXH-105 or Shingrix.
- Conditions
- Herpes Zoster (HZ), Infectious Diseases, Shingles
- Trial name
- NCT06581575
- Testing
- JCXH-105, Shingrix
- Where
- 8 sites in United States
- Volunteers
- 467 people, healthy volunteers welcome
- Sponsor
- Immorna Biotherapeutics, Inc.
Varicella (Chickenpox), Varicella Immunisation
Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Vietnamese Children
This is a single armed, Phase 3 study to assess the immunogenicity and safety of the varicella vaccine manufactured by Sinovac. A total of 300 healthy participants aged 1-12 years will be enrolled.
- Trial name
- NCT07473427
- Testing
- Varicella Vaccine
- Where
- Vietnam
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Varicella
Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
This a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd .The purpose of this study is to evaluate the immunogenicity of a two doses…
- Trial name
- NCT05015686
- Testing
- Live attenuated varicella vaccines manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd, Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,Ltd
- Where
- China
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster
Immunogenicity and Safety of SYS6017 in the Participants Aged 40 Years and Above
Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging.
- Trial name
- NCT07354659
- Testing
- A zoster mRNA vaccine SYS6017, Active Comparator Vaccine
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- CSPC Megalith Biopharmaceutical Co.,Ltd.
Varicella (chickenpox), MMR Vaccine
Study of Live Attenuated Varicella Vaccine Co-administered with MMR Vaccine or DTaP Vaccine
This is a phase Ⅳ clinical trial of live attenuated varicella vaccine manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.The primary objective of this study is to evaluate the immunogenicity of live attenuated varicella…
- Conditions
- Varicella (chickenpox), MMR Vaccine, DTaP Vaccine
- Trial name
- NCT06891872
- Testing
- Vaicella Vaccine+DTaP on Day 0, MMR on Day 30, Varicella vaccine+MMR on Day 0，DTaP on Day 30, Varicella Vaccine
- Where
- China
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sinovac (Dalian) Vaccine Technology Co., Ltd.
Herpes Zoster
Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30.
- Trial name
- NCT07099157
- Testing
- Brivudine, Famciclovir
- Where
- 4 sites in China
- Volunteers
- 140 people
- Sponsor
- Peking University Third Hospital
Herpes Zoster, Immunologic Deficiency Syndromes
Randomized Study of Two Doses of Oral Valacyclovir in Immunocompromised Patients With Uncomplicated Herpes Zoster
OBJECTIVES: I. Compare the efficacy and safety of two doses of oral valacyclovir in immunocompromised patients with uncomplicated herpes zoster. II.
- Trial name
- NCT00006131
- Testing
- Valacyclovir
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- National Center for Research Resources (NCRR)
Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates
Response to the SHINGRIX Varicella Zoster Virus (VZV) Vaccine in Chronic Lymphocytic Leukemia (CLL) and CLL Treated With Bruton's Tyrosine Kinase Inhibitor (BTK-I)
Background: People who have cancer tend to get sick more often. This is in part because of the cancer treatments they get. Because of this, they may get shingles.
- Conditions
- Safety and Tolerability, Compare SHINGRIX Vaccine Response Rates, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
- Trial name
- NCT03702231
- Testing
- Zoster Vaccine Recombinant, Adjuvanted
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Varicella, Rubella
Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM
The purpose of this study is to assess non-inferiority of two different vaccination regimens using GSK Biological's MMRV vaccine (two doses at 9 and 15 months) or Priorix™ (9 months) and one dose of MMRV vaccine (15 months) to…
- Conditions
- Varicella, Rubella, Mumps, Measles
- Trial name
- NCT00969436
- Testing
- GSK Biological's investigational MMRV vaccine 208136, Priorix™, Varilrix™
- Where
- 6 sites in India
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline